Irem Karaman Sebin/X
Oct 18, 2026, 00:07
Irem Karaman Sebin: The Evidence Favoring Warfarin in High-Risk Antiphospholipid Syndrome
Irem Karaman Sebin, Internal Medicine Resident at Florida International University – Herbert Wertheim College of Medicine, shared a post on X:
“Today I learned that antiphospholipid syndrome is the only major thrombophilia with randomized trial evidence favoring warfarin over DOACs, particularly in high-risk patients with arterial thrombosis, possibly due to inhibition of multiple vitamin K–dependent coagulation factors, although the mechanism remains unclear.”
Stay udpated with Hemostasis Today.
-
Oct 18, 2026, 00:33Elad Asher: Does Opening the Clot Change How a Patient Feels Three Months Later?
-
Oct 18, 2026, 00:22Richa Sharma: Evaluating Heterogeneity in Anticoagulation Treatment Effects in Cryptogenic Stroke
-
Oct 18, 2026, 00:07Emma Stevens: Lighting Up Buildings in Red and Blue for World Thrombosis Day
-
Oct 17, 2026, 23:18Maha Othman: Establishing ISTH-BAT Reference Ranges for Children and Adolescents
-
Oct 17, 2026, 17:27John Strouse: Building Standards for Whole-Person Sickle Cell Care Through Collaboration
-
Oct 17, 2026, 17:20Jean-Jacques Kiladjian: Exploring the Future of Polycythemia Vera Treatment at MPN Horizons 2026
-
Oct 17, 2026, 17:10Habib Bennaceur: Strengthening Collaboration in Haemophilia, Sickle Cell Disease and Thalassaemia in India
-
Oct 17, 2026, 16:58Danny Hsu: Building Connections at the AUSNBled Collaborative Dinner in Auckland
-
Oct 17, 2026, 16:48Kalyan Roy: Enhancing Patient Experience Through Learning and Collaboration